Human Oncology & Pathogenesis Program
The Marc Ladanyi Lab
Research
The research program in this laboratory focuses on the genomics and molecular pathogenesis of sarcomas and thoracic malignancies, with an emphasis on clinical translation of potential diagnostic markers and therapeutic targets. Dr. Ladanyi also co-directs (with Chris Sander) the Genome Data Analysis Center at Memorial Sloan Kettering, which is part of the TCGA project network.
Examples of recent contributions include the validation of DUSP4 as a driver gene for 8p losses in EGFR-mutant lung adenocarcinomas, the establishment of methods for enhanced detection of the EGFR T790M secondary mutation in the setting of acquired resistance to EGFR inhibitors, the discovery of BAP1 mutations in mesotheliomas with 3p losses, the identification of novel, recurrent HEY1-NCOA2 and KIF5B-RET fusions in mesenchymal chondrosarcoma and lung adenocarcinoma, respectively, both based on mining of exon-level expression data, as well as major involvement in the TCGA Network marker papers on the genomics of glioblastoma, ovarian carcinoma, and squamous lung cancer. Ongoing projects are addressing further questions in lung adenocarcinoma, mesothelioma, and several sarcoma types using whole exome and whole transcriptome sequencing, ChIP-seq, Sequenom mass spectrometry genotyping, NanoString expression profiling, RNAi screens, chemical screens, and proteomic approaches.
Featured News
Publications Highlights
People
Marc Ladanyi, MD
- Molecular pathologist Marc Ladanyi studies the molecular pathogenesis of sarcomas, lung cancer, and mesothelioma.
- MD, McGill University
- 212-639-6369
- Office Phone
- View physician profile
- Physician profile
Members
Lab Alumni
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Career Opportunities
Get in Touch
-
Office Phone
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Marc Ladanyi discloses the following relationships and financial interests:
-
Bayer Inc.
Professional Services and Activities -
Paige.AI, Inc.
Equity; Professional Services and Activities (Uncompensated)
-
SOPHiA GENETICS S.A.
Intellectual Property Rights
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].